FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080392435> ?p ?o ?g. }

• W3080392435 endingPage "1266" @default.
• W3080392435 startingPage "1257" @default.
• W3080392435 abstract "Nivolumab plus ipilimumab combination is currently one of the preferred regimens for advanced melanoma in recently updated clinical practice guidelines. However, the evidence on the efficacy of the combination for acral or mucosal subtypes remains less robust. This is the final analysis of a multicenter, open-label, uncontrolled phase II study that investigated the long-term efficacy and safety in treatment-naive Japanese patients with advanced melanoma, including acral or mucosal subtypes, and subsequent therapy after discontinuation of the investigational agents. Patients received four doses of nivolumab (1 mg/kg i.v.) in combination with ipilimumab (3 mg/kg i.v.) at 3-week intervals, followed by doses of nivolumab (3 mg/kg i.v.) at 2-week intervals. The median follow-up period was 20.8 months (range, 5.2–35.0). The centrally and locally assessed objective response rates were both 43.3% (13/30; 95% confidence interval [CI], 25.5–62.6). Median progression-free survival was not reached (95% CI, 3.02–not reached), and median overall survival was also not reached (95% CI, 19.52–not reached). The 30-month progression-free survival and overall survival rates were 50.3% and 54.2%, respectively. No new safety concerns were detected. After discontinuation of the investigational agents, 83.3% of patients received some form of subsequent therapy including 43.3% of patients who received nivolumab monotherapy and 26.7% of patients who received radiotherapy. Of the four patients who discontinued the investigational agents because of immune-related adverse events, two received subsequent therapy (nivolumab and ipilimumab, respectively) and the other two showed long-term treatment-free survival (659 and 590 days, respectively). Long-term survival with nivolumab plus ipilimumab was observed in Japanese patients with melanoma including acral and mucosal subtypes, which is consistent with the CheckMate 067 study. Many patients continued to receive some form of treatment safely after stopping treatment with nivolumab plus ipilimumab." @default.
• W3080392435 created "2020-09-01" @default.
• W3080392435 creator A5001893646 @default.
• W3080392435 creator A5002901596 @default.
• W3080392435 creator A5042799216 @default.
• W3080392435 creator A5047984722 @default.
• W3080392435 creator A5050952919 @default.
• W3080392435 creator A5056288611 @default.
• W3080392435 creator A5059052214 @default.
• W3080392435 creator A5060874420 @default.
• W3080392435 creator A5065106305 @default.
• W3080392435 creator A5068079253 @default.
• W3080392435 creator A5080001880 @default.
• W3080392435 creator A5084895308 @default.
• W3080392435 creator A5089137663 @default.
• W3080392435 date "2020-08-18" @default.
• W3080392435 modified "2023-09-27" @default.
• W3080392435 title "Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma" @default.
• W3080392435 cites W1849671624 @default.
• W3080392435 cites W2017095180 @default.
• W3080392435 cites W2034248634 @default.
• W3080392435 cites W2079854108 @default.
• W3080392435 cites W2119787454 @default.
• W3080392435 cites W2128758225 @default.
• W3080392435 cites W2166662937 @default.
• W3080392435 cites W2408787182 @default.
• W3080392435 cites W2513097773 @default.
• W3080392435 cites W2519279652 @default.
• W3080392435 cites W2519469881 @default.
• W3080392435 cites W2553340100 @default.
• W3080392435 cites W2733884328 @default.
• W3080392435 cites W2742763599 @default.
• W3080392435 cites W2753432434 @default.
• W3080392435 cites W2772954720 @default.
• W3080392435 cites W2792937256 @default.
• W3080392435 cites W2890146531 @default.
• W3080392435 cites W2901290714 @default.
• W3080392435 cites W2912374321 @default.
• W3080392435 cites W2947597271 @default.
• W3080392435 cites W2976744492 @default.
• W3080392435 cites W2978880457 @default.
• W3080392435 cites W2981443129 @default.
• W3080392435 cites W2990190467 @default.
• W3080392435 cites W3000619658 @default.
• W3080392435 cites W3013646646 @default.
• W3080392435 cites W3043703771 @default.
• W3080392435 cites W4256631179 @default.
• W3080392435 doi "https://doi.org/10.1111/1346-8138.15514" @default.
• W3080392435 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7693067" @default.
• W3080392435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32812243" @default.
• W3080392435 hasPublicationYear "2020" @default.
• W3080392435 type Work @default.
• W3080392435 sameAs 3080392435 @default.
• W3080392435 citedByCount "12" @default.
• W3080392435 countsByYear W30803924352020 @default.
• W3080392435 countsByYear W30803924352021 @default.
• W3080392435 countsByYear W30803924352022 @default.
• W3080392435 countsByYear W30803924352023 @default.
• W3080392435 crossrefType "journal-article" @default.
• W3080392435 hasAuthorship W3080392435A5001893646 @default.
• W3080392435 hasAuthorship W3080392435A5002901596 @default.
• W3080392435 hasAuthorship W3080392435A5042799216 @default.
• W3080392435 hasAuthorship W3080392435A5047984722 @default.
• W3080392435 hasAuthorship W3080392435A5050952919 @default.
• W3080392435 hasAuthorship W3080392435A5056288611 @default.
• W3080392435 hasAuthorship W3080392435A5059052214 @default.
• W3080392435 hasAuthorship W3080392435A5060874420 @default.
• W3080392435 hasAuthorship W3080392435A5065106305 @default.
• W3080392435 hasAuthorship W3080392435A5068079253 @default.
• W3080392435 hasAuthorship W3080392435A5080001880 @default.
• W3080392435 hasAuthorship W3080392435A5084895308 @default.
• W3080392435 hasAuthorship W3080392435A5089137663 @default.
• W3080392435 hasBestOaLocation W30803924352 @default.
• W3080392435 hasConcept C121608353 @default.
• W3080392435 hasConcept C126322002 @default.
• W3080392435 hasConcept C141071460 @default.
• W3080392435 hasConcept C143998085 @default.
• W3080392435 hasConcept C197934379 @default.
• W3080392435 hasConcept C2776694085 @default.
• W3080392435 hasConcept C2776999253 @default.
• W3080392435 hasConcept C2777658100 @default.
• W3080392435 hasConcept C2777701055 @default.
• W3080392435 hasConcept C2778715236 @default.
• W3080392435 hasConcept C2780030458 @default.
• W3080392435 hasConcept C2780739268 @default.
• W3080392435 hasConcept C2781433595 @default.
• W3080392435 hasConcept C44249647 @default.
• W3080392435 hasConcept C502942594 @default.
• W3080392435 hasConcept C71924100 @default.
• W3080392435 hasConcept C90924648 @default.
• W3080392435 hasConceptScore W3080392435C121608353 @default.
• W3080392435 hasConceptScore W3080392435C126322002 @default.
• W3080392435 hasConceptScore W3080392435C141071460 @default.
• W3080392435 hasConceptScore W3080392435C143998085 @default.
• W3080392435 hasConceptScore W3080392435C197934379 @default.
• W3080392435 hasConceptScore W3080392435C2776694085 @default.
• W3080392435 hasConceptScore W3080392435C2776999253 @default.
• W3080392435 hasConceptScore W3080392435C2777658100 @default.

• next